Le Lézard
Classified in: Science and technology, Business
Subjects: FNC, VEN

Graceview raises $1.5M to fuel growth


MELBOURNE, Australia, Aug. 5, 2024 /PRNewswire/ -- Graceview today announced its successful completion of a funding round totalling $1.5M.

Key points

Building the future

Graceview, a leader in generative AI for compliance, today announced its successful completion of a funding round totalling $1.5M.

With leading global corporates already among its growing client base, this investment will accelerate the commercial rollout of Graceview's platform to fuel growth.

The round was led by Singapore-based entrepreneur, Patrick Linton and brings together a consortium of tech founders and investors.

Graceview leverages AI, machine learning, legal knowledge integrations, and data analytics to deliver real-time insights on compliance threats and opportunities. The platform combines the speed and efficiency of generative AI with senior lawyer oversight to streamline regulatory compliance, and to maintain an environment of continuous compliance.

Simon Quirk, Co-Founder & CEO of Graceview, said:

We are incredibly pleased to have investors who are business people and technology founders backing our vision for the future of compliance. The scale of the compliance problem for large corporates is rapidly increasing and existing solutions are difficult and expensive. By combining generative AI with senior lawyer oversight, we have shown that it's now possible to continuously and cost-effectively manage regulatory change and deliver on our vision of making the whole process effortless. We are excited to work with our investors and utilise this investment to build on our revenue growth and to scale our product and operations, with an immediate focus on Asia-Pacific and UK/European markets.

Patrick Linton, who will be joining Graceview's Board of Directors, added: 

We are thrilled to partner with Graceview at this pivotal moment and recognise the transformative potential their platform offers corporates to easily remain compliant. The integration of leading-edge AI technology with senior legal expertise sets a new standard in regulatory compliance, ensuring both agility and precision. We are committed to supporting Graceview as they expand their reach across global markets.

Graceview is currently located in Melbourne, London and Singapore.

About Graceview

Graceview is a legal generative AI company founded by a trio of lawyer-computer scientists with 30+ years of experience at the forefront of AI and law. Graceview is the AI-driven platform for effortless regulatory compliance, empowering legal, risk and compliance teams worldwide. Our mission is to create a world where compliance is easy and continuous.


These press releases may also interest you

at 07:05
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial during an oral presentation on...

at 07:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the...

at 07:05
CDR-Life today announced significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company's mission to deliver innovative, antibody-fragment based immunotherapies for difficult-to-treat cancers....

at 07:05
PG Forsta, the leading provider of experience measurement, data analytics and insights for healthcare and other complex industries, held its annual Community Day in South Bend, Ind. on Thursday, September 12. Community Day is PG Forsta's annual day...

at 07:05
WiSA Technologies, Inc. in definitive agreement to acquire assets of Data Vault Holdings, Inc.® to form a data technology & licensing company leveraging IP & proprietary HPC software, announces WiSA CEO Brett Moyer and Data Vault CEO Nate Bradley...

at 07:00
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of...



News published on and distributed by: